Vowing to spark a revolution in small molecule R&D, Vividion equips itself with an extra $82M for the final stretch to the clinic
Vividion Therapeutics has come a long way in the little more than 2 years since the company officially launched with a $45 million A round in early 2017. CEO Diego Miralles has been building his San Diego-based team and banking cash along the way, adding a $101 million deal with Celgene — including a $97 million upfront — for a soon-to-be-acquired biotech player with a big appetite for external discovery alliances.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.